PatientsVille.com Logo

Skin and Olay

PatientsVille

Skin Symptoms and Causes

Your Skin is your body's largest organ. It covers and protects your body. Your Skin

  • Holds body fluids in, preventing dehydration
  • Keeps harmful microbes out, preventing infections
  • Helps you feel things like heat, cold, and pain
  • Keeps your body temperature even
  • Makes vitamin D when the sun shines on it

Anything that irritates, clogs, or inflames your Skin can cause symptoms such as redness, swelling, burning, and itching. Allergies, irritants, your genetic makeup, and certain diseases and immune system problems can cause rashes, hives, and other Skin conditions. Many Skin problems, such as acne, also affect your appearance.

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Check out the latest treatments for skin

skin treatment research studies

Olay clinical trials, surveys and public health registries


Find Drug Side Effect reports



Olay Side Effects

Eyelid Oedema (69)
Skin Disorder (40)
Blister (35)
Condition Aggravated (31)
Swelling Face (30)
Dyspnoea (25)
Erythema (17)
Skin Exfoliation (14)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

A rather large, painless bubble on my foreskin.

After a month of exfoliating my face is peeling off

After the first gardisil shot i started getting a redish brown line following my hip bone then it spread to my upper stomach, just solid around the abdominal area. After i got a small itchy red dot on my back and about a month later it turned into a

Could my daughters psoriasis have anything to do with her old english sheepdog who urinates everywhere and sleeps in and on her bed?

Dear sir I'm asking about CO2 foot bath therapy devices JAPANESE TECHNOLOGY FROM MITSUBISHI DIABETIC PATIENTS coast please Regards Safa Azawi Iraq

Feet skin tight and itchy some fluid retention - hot feet.Take Nexium and Imdur

I have ocnstant and irrepressible mouth moveements accmpanied by a sort of internal chanting of nonsensical sounds. This started several months after starting adderol so I stopped it but my psychiatrist and a neurologist don't think that is the cause

It works very well. I am upset that I can't find it anymore

Large area started as a bruise now blistering really hard underneath turning tan to greenish

My man had littles bumps on his face that looked like pimples, he was trying to pop it and he wash his face n put on a acne cream but it just made it worse not his face were the bumps or pimples were is red swollen and dried out and its paining him w

48 years of age. I was diagnosed with urinary tract infection. Had one dose of monuril 3 gr. After 7 hours developed skin rash on the back, arms and neck, generally swelling of the face, specially below the eyes, Had oral antihistamine and went to

As mentioned in many reviews i have read I experienced the first 2 months with lots of purging white heads etc. Now my skin is clear and smooth with scars clearing rapidly. Over the last 3 weeks i am experiencing nausea and headaches mild to heav

THE SKIN AROUND BOTH MY THUMBS ALL THE SIDE OF MY POINTER FINGER THE TIP OF ONE OF MY MIDDLE FINGER AND AT ONE POINT ON MY PALM RIGHT UNDER MY THUMBS, LOOK SO TERRIBLE. MY SKIN ON THOSE AREAS ARE VERY ROUGH AND SCALING ALSO THEY HAVE A GREENISH COLO

<b>Describe Your Dramamine Experience Here:</b> I injected Dramamine 70year old female I diluted Dramamine with nss 10 ml then bolus in 5 minute and I'm sure it not leak but after finish injected an area skin become to be a redness and w

I was given Celestene by a GP in Frace for bronchial problems/ashma - 4mg for 10 days. It gave me really irritated red skin with spots, overy sensitive skin to my face which tingled when touched, stomach problems and blured vision

I am of 53 suffering with skin problem for several years. Doctors are unable to diagnose the exact problem. Some doctors say it is Urticaria, some say it is some sort of Eczema and so on. The currentphysician advised to

I bought the advanced Aveeno facial skin care kit/package. Specifically it w as the Aveeno 'Positively Ageless' 4 step skin care package. Well, within a week I had strange bumps on my neck, on the back of my shoulders and patches of disco

I have been taking Ezetrol for 6 months without any side effects but now i have developed muscle pain in my right leg and my skin is very itchy. I have also reported pains in the stomach and under my right side ribs but she said

<strong></strong><span style='color: #476cb8;'><span style='cursor: pointer;'>??<span style='display: none;'> THERE IS SOMETHING COMING OUT OF MY BUTT ITS EXTRA SKIN AN

<strong>Found Celepram effective at the end of the 3rd week. Effectiveness lasted for around 14 days. Following period i experienced continualled short term memory loss, hallucinations of seeing stars, skin irritated rash, shortness of breath &

Skin Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Conditions: Dyskinesia;   Levodopa Induced Dyskinesia (LID);   Parkinson's Disease
Intervention: Drug: ADS-5102
Outcome Measures: Change in the Unified Dyskinesia Rating Scale (UDysRS) score;   Change in the standardized PD home diary (ON time without Dyskinesia, ON time with troublesome Dyskinesia, OFF time);   Change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS);   Clinician's Global Impression of Change in overall PD symptoms
2 Not yet recruiting Efficacy and Safety of Amantadine ER Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.
Conditions: Parkinson's Disease;   Levodopa Induced Dyskinesia (LID)
Interventions: Drug: Amantadine ER Tablets;   Drug: Placebo Tablets for Amantadine ER Tablets
Outcome Measures: Unified Dyskinesia Rating Scale (UDysRS);   Mobility State Self-Assessment (Subject Diary Cards);   MDS-UPDRS;   Fatigue Severity Scale
3 Not yet recruiting Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias
Conditions: Parkinson's Disease;   Levodopa Induced Dyskinesia (LID)
Interventions: Drug: Amantadine HCl ER (ALLAY-LID II);   Drug: Placebo
Outcome Measures: Unified Dyskinesia Rating Scale;   Mobility State Self Assessment (Subject Diary Cards);   Mobility State Self-Assessment (Subject Diary Cards);   MDS-Unified Parkinson's Disease Rating Scale;   Fatigue Severity Scale
4 Recruiting Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Conditions: Idiopathic Parkinson's Disease;   Drug Induced Dyskinesia
Intervention: Drug: Topiramate
Outcome Measures: The Unified Dyskinesia Rating Scale (UDysRS);   Clinical Global Impression - Change score
5 Recruiting Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Conditions: Dyskinesia;   Parkinson's Disease
Interventions: Drug: AVP-923-45;   Drug: Placebo
Outcome Measures: Unified Dyskinesia Rating Scale (UDysRS), part 3;   UDysRS, part 4;   Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III-motor score;   Bradykinesia;   MDS-UPDRS part I, II, and IV;   UDysRS part 1 and 2;   PD Motor Diary
6 Recruiting A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson's Disease
Condition: Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
Intervention: Device: transcranial magnetic resonance guided focused ultrasound pallidotomy
Outcome Measure: the unified Dyskinesia rating scale (UdysRS) and UPDRS part IV
7 Recruiting Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia
Conditions: Cystic Fibrosis;   Primary Ciliary Dyskinesia
Interventions: Procedure: Sputum Collection;   Procedure: Pulmonary Function Testing;   Procedure: Exhaled Nitric Oxide
Outcome Measures: Change in sputum bacterial colony count;   Airway Inflammatory Profile;   Culture, identification, and antibiotic susceptibility pattern of respiratory pathogens from sputum samples;   Tolerability and need for sputum induction in Cystic Fibrosis (CF) patients in comparison to Primary Ciliary Dyskinesia (PCD) patients;   Change in forced expiratory volume in 1 second (FEV1) in response to a treatment course of antibiotics for pulmonary exacerbation.;   Other markers of airway inflammation
8 Unknown  Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
Condition: Dyskinesia, Drug-Induced
Intervention: Drug: aripiprazole
Outcome Measures: Total scores of AIMS;   Total scores of PANSS;   Total scores of SAS
9 Recruiting Otolith Function in Patients With Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention: Other: Utricular centrifugation test, vestibular evoked myogenic potentials & ocular counter-rolling test
Outcome Measure: The results of the utricular centrifugation test, VEMPs & ocular counter-rolling test
10 Recruiting Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
Condition: Early Parkinson Disease
Interventions: Drug: Amantadine;   Drug: placebo
Outcome Measures: after 18 months of Phase 1 of the study;   abnormal involuntary dyskinetic movements at the end of phase 3 of the study (wash out);   motor fluctuations after 18 months of Phase 1 of the study;   Time to onset of Dyskinesias
11 Unknown  Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Dietary Supplement: Omega-3 fish oil capsules (including DHA);   Dietary Supplement: Placebo
Outcome Measures: Clinical rating scales (AIMS, St.Hans);   Quantitative motor testing (kinematic parameters);   Monitoring of psychopathology (Neuro-Psychiatric Inventory, Positive and Negative Syndrome Scale, Calgary Depression Scale for Schizophrenia);   Erythrocyte membrane phospholipid profile (gas chromatography)
12 Unknown  Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: Pyridoxal 5'-Phosphate;   Drug: Placebo
Outcome Measures: The primary outcome measure will be a reduction in the total AIMS score for items 1 through 7 (facial and oral movements, extremity movements and trunk movements) across treatment groups. .;   An AIMS score reduction (items 1-7) across arms over course of study amongst completers; determine whether the proportion of responders differs between treatment arms; a reduction in the AIMS score, items 1 - 7 total, across treatment arms.
13 Recruiting A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
Condition: Drug-induced Tardive Dyskinesia
Interventions: Drug: Acamprosate calcium;   Drug: Placebo
Outcome Measures: Efficacy as measured by changes from baseline in summary scores on the Abnormal Involuntary Movement Scale (AIMS);   Compare the effectiveness of low dose and high dose of SNC-102;   Assess safety and tolerability of SNC-102 in the tardive Dyskinesia population;   Assess the pharmacokinetic (PK) profile in TD subjects;   Determine the relationship between the PK profile and clinical effects of SNC-102
14 Recruiting Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Condition: Parkinson's Disease
Interventions: Drug: Docosahexaenoic Acid (DHA);   Drug: Placebo
Outcome Measures: Safety/Efficacy of DHA;   Dyskinesia
15 Recruiting Comparison of the Incidence of Dyskinesia in Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist
Condition: Parkinson`s Disease
Intervention:
Outcome Measures: Dyskinesia onset;   UPDRS, severity of Dyskinesia between groups
16 Recruiting D-Serine Treatment For Tardive Dyskinesia
Conditions: Schizophrenia and Schizoaffective Disorder;   Tardive Dyskinesia
Intervention: Dietary Supplement: D-serine
Outcome Measure: Change in AIMS total score
17 Unknown  Early Detection and Characterization of Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention:
Outcome Measure: Phenotypic and genetic characterization
18 Not yet recruiting Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention: Procedure: Chest physiotherapy
Outcome Measures: Difference in FEV1 before and after treatment;   Difference in LCI before and after chest physiotherapy
19 Unknown  Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide
Condition: Primary Ciliary Dyskinesia
Intervention:
Outcome Measure: Nasal NO < 105 ppb
20 Recruiting Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Condition: Tardive Dyskinesia
Interventions: Drug: Tetrabenazine;   Drug: Placebo
Outcome Measures: Changes in ESRS: Extrapyramidal Symptoms Rating Scale;   Changes in Sub-score ESRS-II;   CGI amelioration;   Tolerance;   Changes in Quality of life;   AIMS improvement;   Changes in intermediate ESRS and post-treatment ESRS